[{"orgOrder":0,"company":"ILC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ILC Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ILC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ILC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ILC Therapeutics","sponsor":"Eos Angel Investment Syndicate","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Financing","leadProduct":"Human Alpha Interferon","moa":"INF-alpha-14","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ILC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"ILC Therapeutics \/ Eos Angel Investment Syndicate","highestDevelopmentStatusID":"6","companyTruncated":"ILC Therapeutics \/ Eos Angel Investment Syndicate"},{"orgOrder":0,"company":"ILC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Human Alpha Interferon","moa":"INF-alpha-14","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ILC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"ILC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ILC Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by ILC Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : The financing will be used in the development for ILC’s lead hybrid interferon drug, Alfacyte (human alpha interferon), an anti-viral medicine for the treatment of upper respiratory tract viral infections, including SARS-CoV-2 which causes Covid-19.

                          Product Name : Alfacyte

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          April 26, 2023

                          Lead Product(s) : Human Alpha Interferon

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Eos Angel Investment Syndicate

                          Deal Size : $4.8 million

                          Deal Type : Financing

                          blank

                          02

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : ILC Therapeutics' unique synthetic Interferon called Alfacyte™ is fifteen to twenty times more effective at preventing the spread of SARS-CoV-2 in cell culture than other commercially-available Interferons such as Interferon alpha 2 and Interferon beta...

                          Product Name : Alfacyte

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          July 10, 2020

                          Lead Product(s) : Human Alpha Interferon

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : The company has patented a new Interferon-Alpha subtype called Interferon Alpha 14 which can be given to patients through injection or inhalation.

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          April 30, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank